At the annual American Association of Neurological Surgeons meeting, NuVasive (NUVA) will launch new products including AttraX® Putty Biotextured™ bone graft, the Reline® Modular system, next-gen MAS® TLIF 2 technology, etc.
- AttraX, which recently received FDA 510(k) clearance, is already marketed internationally. This next-gen synthetic biologic product is indicated as an autograft extender in the posterior lateral spine.
- Reline is part of NUVA’s Integrated Global Alignment (iGA™) platform, and is designed to improve visualization and access to the intervertebral disc in TLIF and PLIF.
- The Monolith™ Corpectomy system is a modular, imaging-friendly PEEK implant indicated for use in T1-L5 with supplemental fixation.
For 1Q16, NUVA reported revenue of US $215.1MM, +11.8% from 1Q15, including a quarter of sales from newly-acquired Ellipse Technologies products.
Sources: NuVasive, Inc.; ORTHOWORLD Inc.
At the annual American Association of Neurological Surgeons meeting, NuVasive (NUVA) will launch new products including AttraX® Putty Biotextured™ bone graft, the Reline® Modular system, next-gen MAS® TLIF 2 technology, etc.
AttraX, which recently received FDA 510(k) clearance, is already marketed internationally. This next-gen synthetic...
At the annual American Association of Neurological Surgeons meeting, NuVasive (NUVA) will launch new products including AttraX® Putty Biotextured™ bone graft, the Reline® Modular system, next-gen MAS® TLIF 2 technology, etc.
- AttraX, which recently received FDA 510(k) clearance, is already marketed internationally. This next-gen synthetic biologic product is indicated as an autograft extender in the posterior lateral spine.
- Reline is part of NUVA’s Integrated Global Alignment (iGA™) platform, and is designed to improve visualization and access to the intervertebral disc in TLIF and PLIF.
- The Monolith™ Corpectomy system is a modular, imaging-friendly PEEK implant indicated for use in T1-L5 with supplemental fixation.
For 1Q16, NUVA reported revenue of US $215.1MM, +11.8% from 1Q15, including a quarter of sales from newly-acquired Ellipse Technologies products.
Sources: NuVasive, Inc.; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





